The Aboriginal Cardiovascular Omega-3 Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,090,119.00
Summary
CVD is the primary contributor to life expectancy differentials between Indigenous and non-Indigenous Australians. Even when cardioprotective therapies are optimally used, residual risk of adverse events is often observed. Testing of additional therapies that improve survival among Indigenous people with CVD is required. Omega 3 fatty acids can improve multiple atherogenic pathways. This trial will assess the impact of Omega 3 in Aboriginal patients with CVD.
Brain Repair Following Stroke: The Role Of Npas4, A Neural-specific Transcription Factor
Funder
National Health and Medical Research Council
Funding Amount
$611,053.00
Summary
Stroke is the #1 cause of adult disability in Australia and #2 cause of death. About 60,000 Australians suffer a stroke each year while about 250,000 live with the disabilities of stroke, costing over $2B/year. The Queen Elizabeth Hospital and University of Adelaide will study why the Npas4 gene switches on after stroke and the role it plays in brain repair. Future health benefits may be tests to help improve stroke outcome in patients and therapy to decrease loss of brain cells after stroke.
Life! Diabetes Prevention Program: A Randomised Cluster Control Trial Of Its Efficacy And Cost Effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$866,066.00
Summary
Type 2 diabetes is a great and growing epidemic, and Australia's largest public health challenge. Life! is a diabetes prevention program for 25,000 Victorians. This proposal will look at its efficacy, effectiveness and cost effectiveness so that more improvements can be made.